FOLD · As filed with the SEC

Amicus Therapeutics balance sheet, by fiscal year

The statement as Amicus Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Balance Sheets · USD thousands

USD thousands	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021
Assets
Current assets:
Cash and cash equivalents	214,010	213,752	246,994	148,813	245,197
Investments in marketable securities	79,526	36,194	39,206	144,782	237,299
Accounts receivable, net	115,307	101,099	87,632	66,196	52,672
Inventories, net	228,819	118,782	59,696	23,816	26,818
Prepaid expenses and other current assets	38,511	34,909	49,533	40,209	34,848
Total current assets	676,173	504,736	483,061	423,816	596,834
Operating lease right-of-use assets, net	21,138	22,278	26,312	29,534	20,586
Property and equipment, less accumulated depreciation of $31,821 and $28,775 at December 31, 2025 and 2024, respectively	27,108	29,383	31,667	30,778	42,496
Intangible assets, less accumulated amortization of $9,085 and $5,802 at December 31, 2025 and 2024, respectively	13,915	17,198	20,490	23,000	23,000
Goodwill	197,797	197,797	197,797	197,797	197,797
Other non-current assets	13,739	13,641	18,553	19,242	24,427
Total Assets	949,870	785,033	777,880	724,167	905,140
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	28,630	12,947	15,120	15,413	21,513
Accrued expenses and other current liabilities	200,457	127,300	144,245	93,636	98,153
Contingent consideration payable	—	—	0	21,417	18,900
Operating lease liabilities	8,741	8,455	8,324	8,552	7,409
Total current liabilities	237,828	148,702	167,689	139,018	145,975
Long-term debt	392,660	390,111	387,858	391,990	389,357
Operating lease liabilities	40,962	45,078	48,877	51,578	43,363
Deferred income taxes	—	—	—	4,939	4,930
Deferred reimbursements	—	—	—	4,656	5,906
Other non-current liabilities	4,179	7,097	13,282	8,939	8,240
Total liabilities	675,629	590,988	617,706	601,120	597,771
Stockholders' equity:
Common stock, $0.01 par value, 500,000,000 shares authorized, 310,853,963 and 299,041,653 shares issued and outstanding at December 31, 2025 and 2024, respectively	3,037	2,944	2,918	2,815	2,808
Common stock in treasury, at cost; 7,390 shares as of December 31, 2025	(71)	—	—	—	—
Additional paid-in capital	3,014,456	2,926,115	2,836,018	2,664,744	2,595,419
Accumulated other comprehensive gain (loss):
Foreign currency translation adjustment	24,120	5,302	5,429	(11,989)	5,251
Unrealized loss on available-for-sale securities	(11)	(207)	(188)	(116)	(270)
Warrants	0	71	71	83	83
Accumulated deficit	(2,767,290)	(2,740,180)	(2,684,074)	(2,532,490)	(2,295,922)
Total stockholders' equity	274,241	194,045	160,174	123,047	307,369
Total Liabilities and Stockholders' Equity	949,870	785,033	777,880	724,167	905,140

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.